These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 3188815)
1. [The risk of drug overdosage in hepatic diseases]. Bircher J Acta Gastroenterol Belg; 1988; 51(1):102-5. PubMed ID: 3188815 [No Abstract] [Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of molsidomine in patients with liver dysfunction due to congestive heart failure. Huber T; Grosse-Heitmeyer W; Rietbrock S; Harder S Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):491-2. PubMed ID: 1490800 [No Abstract] [Full Text] [Related]
3. The effects of liver and renal dysfunction on the pharmacokinetics of sedatives and analgesics in the critically ill patient. Yogaratnam D; Miller MA; Smith BS Crit Care Nurs Clin North Am; 2005 Sep; 17(3):245-50. PubMed ID: 16115532 [TBL] [Abstract][Full Text] [Related]
5. [Effect of liver diseases on pharmacokinetics of drugs]. Lazowski J; Rewerski W Pol Tyg Lek; 1990 Feb 5-12; 45(6-7):95-9. PubMed ID: 2216955 [No Abstract] [Full Text] [Related]
12. [Effects of liver disease on pharmacokinetics of drugs and its therapeutic implications]. Nunes AM Rev Port Cardiol; 1992 Feb; 11(2):177-84. PubMed ID: 1567639 [No Abstract] [Full Text] [Related]
14. [Effect of various physiological and pathological conditions on the bioavailability of drugs]. Danysz A; Wierzba K Pol Tyg Lek; 1979 Jan; 34(4):141-3. PubMed ID: 432125 [No Abstract] [Full Text] [Related]
15. Drug elimination in chronic liver diseases. Huet PM; Villeneuve JP; Fenyves D J Hepatol; 1997; 26 Suppl 2():63-72. PubMed ID: 9204411 [No Abstract] [Full Text] [Related]
16. [Pharmacokinetics of thiamphenicol. Behavior in a acute and chronic hepatic insufficiency]. Menz HP; Bezler HJ; Hartmann I; von Oldershausen HF Arzneimittelforschung; 1974 Jan; 24(1):99-102. PubMed ID: 4406121 [No Abstract] [Full Text] [Related]
17. Terminal half-lives of drugs studied in patients with hepatic diseases. Closson RG Am J Hosp Pharm; 1977 May; 34(5):520-4. PubMed ID: 326043 [TBL] [Abstract][Full Text] [Related]
18. [Metabolism of phenylbutazone in the liver (author's transl)]. González Macías J; De Castro del Pozo S Med Klin; 1976 Sep; 71(36):1434-8. PubMed ID: 958107 [TBL] [Abstract][Full Text] [Related]
19. [Clinical pharmacology of calcium inhibitors]. Singlas E; Martre H; Taburet AM Arch Mal Coeur Vaiss; 1985 Nov; 78 Spec No():15-22. PubMed ID: 3937500 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oral immediate-release hydromorphone (Dilaudid IR) in subjects with moderate hepatic impairment. Durnin C; Hind ID; Ghani SP; Yates DB; Molz KH Proc West Pharmacol Soc; 2001; 44():83-4. PubMed ID: 11794005 [No Abstract] [Full Text] [Related] [Next] [New Search]